Sign in

LMNX on NASDAQ

Luminex

Logo: Luminex Corporation, Public domain, via Wikimedia Commons5

American biotechnology company

Luminex Corporation is a biotechnology company which develops, manufactures and markets proprietary biological testing technologies with applications in life-sciences.3 It employed 1,080 people in 2023.1 It is part of DiaSorin.1 Its shares trade on NASDAQ under the symbol LMNX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1998Founded1

Compare with another stock.

  • TickerLMNX on NASDAQ1
  • Industrybiotechnology, biotechnology industry1
  • HeadquartersAustin1
  • Websitewww.luminexcorp.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address12212 Technology Blvd, 512-219-8020, Austin, Tx 787276
  • Filer categoryLarge accelerated filer6
  • LEI5299004PD7MBYRVKM1044
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 29109104

See how the biggest companies compare on our leaderboards

Luminex Corporation is a biotechnology company which develops, manufactures and markets proprietary biological testing technologies with applications in life-sciences.3

Corporate structure

Luminex is part of a group headed by DiaSorin. 5 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • DiaSorin Saluggia, Italy
    • Luminex Austin, Texas, United States
      • Luminex (Canada) Subsidiary · Canada
    • DIASORIN INC. Subsidiary · Stillwater, Minnesota, United States
    • DIASORIN ITALIA S.P.A. Subsidiary · Saluggia, Italy

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

What it owns

What Luminex reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$181.6M8 Dec 31, 2020$165.4M8 Dec 31, 2019+9.8%
Accumulated depreciation$117.5M8 Dec 31, 2020$99.8M8 Dec 31, 2019+17.6%
Property and equipment, net$64.1M8 Dec 31, 2020$65.5M8 Dec 31, 2019−2.1%
Operating-lease assets (leased space)$17.8M8 Dec 31, 2020$20.4M8 Dec 31, 2019−13.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$309.4M8 Dec 31, 2020$59.2M8 Dec 31, 2019+422.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$118.1M8 Dec 31, 2020$118.1M8 Dec 31, 20190%
Intangible assets, net (excluding goodwill)$78.8M8 Dec 31, 2020$90.3M8 Dec 31, 2019−12.8%
Indefinite-lived intangibles (excluding goodwill)$17.3M8 Dec 31, 2020$20.0M8 Dec 31, 2019−13.4%
Accumulated amortization$74.8M8 Dec 31, 2020$63.2M8 Dec 31, 2019+18.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$123.1M8 Dec 31, 2020$77.1M8 Dec 31, 2019+59.7%
Work in process$18.9M8 Dec 31, 2020$15.5M8 Dec 31, 2019+21.4%
Finished goods$17.9M8 Dec 31, 2020$16.1M8 Dec 31, 2019+11.2%

The story

Luminex's Multi-Analyte Profiling (xMAP) technology allows simultaneous analysis of up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres.

The xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, light emitting diodes (LEDs), digital signal processors, photo detectors, charge-coupled device imaging and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. The technology is currently being used within various segments of the life sciences industry, which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research.

The Luminex MultiCode technology is used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. Luminex Corporation owns 315 issued patents worldwide, including over 124 issued patents in the United States based on its multiplexing xMAP platform.

In 2021, Luminex was acquired by DiaSorin, an Italian diagnostics firm, for $1.8 billion.

From Wikipedia’s article on Luminex Corporation, shared under CC BY-SA 4.0.7

Leadership

Who has led Luminex, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Patrick J. Balthrop2006–2014
  2. Nachum Shamir2014–2021

President

  1. Patrick J. Balthrop2006–2014
  2. Nachum Shamir2014–2021

Chief financial officer

  1. Harriss T. Currie2006–2021

Chief operating officer

  1. Douglas C. Bryant2007–2008
200020052010201520202025
Board members and other officers (33)

Subsidiaries and ownership

Parent company

Subsidiaries

  • Luminex (Canada)

From Wikidata.1

Employees over time

  • 20231,0801

Timeline

  1. Jul 14, 2021Acquired Acquired by DiaSorin1
  2. Oct 16, 2014New chief executive Nachum Shamir becomes CEO9
  3. Apr 7, 2006New chief executive Patrick J. Balthrop becomes CEO10
  4. Mar 30, 2000Went public Listed on NASDAQ1
  5. 1998Founded Founded1

SEC filer profile

How Luminex is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLUMINEX CORP2
  • CIK0001033905
  • Employer ID (EIN)74-27476082
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
  • Business address12212 Technology Blvd, 512-219-8020, Austin, TX 787272
  • Mailing address12212 Technology Blvd, Austin, TX 787272
  • Phone51224947412
  • Shares outstanding47,313,816 as of May 4, 202144
  • Public float$1.3B as of Jun 30, 20208
  • On EDGAR sinceFeb 7, 20002
  • Filings1,228 in all: 4 (695), 8-K (182), SC 13G/A (67), 10-Q (64), SC 13G (25), 3 (24), 10-K (21), DEF 14A (21)2
    All 38 form types

    DEFA14A (19), 4/A (12), S-8 POS (12), S-8 (11), ARS (10), 8-K/A (9), SD (7), UPLOAD (7), 5 (6), CORRESP (5), S-1/A (4), 144 (3), SC TO-T/A (3), 10-K/A (2), 10-Q/A (2), 8-A12G (2), SC TO-C (2), 15-12G (1), 25-NSE (1), 424A (1), 424B1 (1), 424B2 (1), 424B5 (1), 5/A (1), DEFM14A (1), DFAN14A (1), PREM14A (1), S-1 (1), S-3ASR (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2021
    Quarterly report (10-Q) May 5, 2021
    Proxy statement (DEF 14A) Mar 31, 2021
    Latest 8-K (8-K) Jul 14, 2021

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44